Abstract Number: 1504 • ACR Convergence 2023
Characteristics and Prior Treatment Journey of Systemic Lupus Erythematosus (SLE) Patients Who Were Prescribed Anifrolumab — Observations from the American Rheumatology Network (ARN) in the U.S
Background/Purpose: FDA-approved for moderate-severe SLE in August 2021, anifrolumab is a type I interferon (IFN) receptor antagonist that has been shown to decrease lupus flares…Abstract Number: 1601 • ACR Convergence 2023
Interleukin-6 Disrupts Blood-cerebrospinal Fluid Barrier Permeability in Murine Neuropsychiatric Lupus
Background/Purpose: In exploring the pathogenic mechanisms underlying neuropsychiatric lupus (NPSLE), it was discovered that cerebrospinal fluid (CSF) from lupus patients often contains neurotoxic antibodies, cytokines,…Abstract Number: 1705 • ACR Convergence 2023
Reduced DNASE1L3 Activity and Increased Anti-NET Protective Antibodies Contributes to Accumulation of Neutrophil Extracellular Traps in Pediatric SLE Patients
Background/Purpose: Pediatric systemic lupus erythematosus (pSLE) is a multisystemic chronic autoimmune disease with high renal involvement. In SLE, neutrophil extracellular traps (NETs) are considered a…Abstract Number: 2063 • ACR Convergence 2023
Training to Increase Minority Enrollment in Lupus Clinical Trials with CommunitY Engagement (TIMELY): Assessing Behavioral Predictors of Clinical Trial Referrals Among Healthcare Providers
Background/Purpose: The aim of this study is to assess outcomes among healthcare providers in the American College of Rheumatology's (ACR) Training to Increase Minority Enrollment…Abstract Number: 2269 • ACR Convergence 2023
Evaluating Global Patterns in Treatment and Prevalence of Glucocorticoid Related Comorbidities in Systemic Lupus Erythematosus: An International Study
Background/Purpose: Regional disparities in the management of SLE are frequently described. Governance, funding, logistic barriers, and physician choice may be important determinants though data is…Abstract Number: 2286 • ACR Convergence 2023
Systemic Lupus Erythematosus and Functional Work Disability: A Qualitative Perspective Using a Work Disability Prevention Approach
Background/Purpose: Work participation meaningfully influences mental wellbeing, health-related quality of life, and disease-related outcomes in individuals with systematic lupus erythematosus (SLE). Previous studies estimate that…Abstract Number: 2303 • ACR Convergence 2023
Are Neuropsychiatric Symptoms in Systemic Lupus Erythematosus (NPSLE) Associated with More Frequent Hospitalizations or Exposure to a Greater Number of Immunosuppressive Medications?
Background/Purpose: Neuropsychiatric (NP) symptoms occur in >50% of patients with systemic lupus erythematosus (SLE). A major barrier to research includes the non-specific nature of neuropsychiatric…Abstract Number: 2319 • ACR Convergence 2023
Changes in the Causes and Predictors of Lupus Mortality in Spain Through the Last Decades: Data from the RELESSER Registry
Background/Purpose: The mortality in Systemic Lupus Erythematosus (SLE) varies largely across different countries most probably due to social, healthcare and ethnic differences. We need to…Abstract Number: 2337 • ACR Convergence 2023
Safety and Tolerability of NIM-1324, an Oral, Once-daily LANCL2 Agonist, in a Randomized, Double-Blind, Placebo-Controlled Phase 1 Study in Normal Healthy Volunteers
Background/Purpose: Systemic lupus erythematosus is a complex disease in which the immune system is dysfunctional at multiple levels including impaired regulatory responses, altered self-antigen processing…Abstract Number: 2445 • ACR Convergence 2023
Targeting of Endothelial Dysfunction in Lupus Nephritis: Effect on Human Renal Endothelial Cell Gene Expression and Outcomes in Murine Lupus Nephritis
Background/Purpose: Lupus nephritis (LN) constitutes one of the most severe manifestations of systemic lupus erythematosus (SLE). Evidence points to endothelial nitric oxide synthase (eNOS) uncoupling,…Abstract Number: 2500 • ACR Convergence 2023
Suicidal Ideation and Self-Efficacy in Systemic Lupus Erythematosus: Georgians Organized Against Lupus (GOAL) Cohort
Background/Purpose: Suicidal ideation is more common in SLE than in other chronic diseases. Targeted interventions are needed to reduce morbidity and mortality. Bandura’s theory of…Abstract Number: 2590 • ACR Convergence 2023
Association Between Frailty and Readmissions in Hospitalized Patients with Systemic Lupus Erythematosus (SLE)
Background/Purpose: SLE has one of the highest 30-day hospital readmission rates among chronic conditions1. Frailty is common2 and associated with hospitalization3 in SLE, but whether…Abstract Number: 0046 • ACR Convergence 2023
Circulating Monocytes in RA, SSc, and SLE Have Radically Altered and Unique Transcriptional & Epigenetic Profiles
Background/Purpose: Rheumatoid arthritis (RA), Systemic lupus erythematosus (SLE), and Systemic sclerosis (SSc) are all systemic rheumatic autoimmune diseases with a dysregulated myeloid compartment. Monocytes are…Abstract Number: 0154 • ACR Convergence 2023
Impact of Social Determinants of Health (SDoH) on Survey Response Times Among Lupus Patients
Background/Purpose: Social determinants of health (SDoH) significantly impact outcomes of Systemic lupus erythematosus (SLE) patients. However, little is known about the influence of SDoH on…Abstract Number: 0193 • ACR Convergence 2023
Social Vulnerability Associations with Mortality in a Lupus Cohort
Background/Purpose: The goal of this study is to identify characteristics of socially vulnerable environments associated with increased mortality in a South Carolina systemic lupus erythematosus…
- « Previous Page
- 1
- …
- 36
- 37
- 38
- 39
- 40
- …
- 150
- Next Page »